precision oncology

Photo: Dr. James Creeden, Global Medical Director of Foundation Medicine​. Credit: Foundation Medicine.

By Dean Koh January 10, 2019
Launched in 2010 with a $25 million Series A financing led by Third Rock Ventures, Foundation Medicine released its first commercial assay called FoundationOne in 2012. The company develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumours, hematologic malignancies, and sarcomas. In December 2017, the company’s assay FoundationOne...

Credit: Foundation Medicine

By Dean Koh November 29, 2018
Roche announced last week the launch of FoundationOne CDx, Foundation Medicine’s comprehensive companion diagnostic test for personalised cancer care in Singapore. According to the official media release, FoundationOne CDx supports clinicians in their decision-making by providing a clear, in-depth report that describes the unique genomic profile of a patient’s tumour as well as associated,...
By Dave Muoio July 19, 2018
The Department of Veterans Affairs and IBM Watson Health have announced a one-year extension to an ongoing public-private partnership applying the AI company’s technology to genomic data for cancer therapy. The precision oncology collaboration has so far assisted the treatment of more than 2,700 veterans, according to a statement, although the original agreement in 2016 had proposed the lofty...

Editor's Pick